MN57 | 671212-27-4

• 英文名称: MN57
• 英文别名: 1-[4-(4-Fluorophenyl)sulfonylpiperazin-1-yl]-2-(methylamino)ethanone
• CAS: 671212-27-4
• 化学式: C₁₃H₁₈FN₃O₃S
• 分子量: 315.369
• InChiKey: PICQJFNZNQQNBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  异丙基磺酰氯 、 MN57 在 三乙胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以30%的产率得到Propane-2-sulfonic acid {2-[4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-2-oxo-ethyl}-methyl-amide
  参考文献：
  名称：

  Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

  摘要：

  Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.10.025
• 作为产物：
  描述：

  tert-butyl ester of [2-(4-benzylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamic acid 在 palladium on activated charcoal 盐酸 、 甲酸铵 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 56.0h， 生成 MN57
  参考文献：
  名称：

  Structure–activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

  摘要：

  Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.10.025